Zamtocabtagene autoleucel - Miltenyi Biomedicine
Alternative Names: Anti-CD20-anti-CD19 CAR T cells - Miltenyi Biotec; Anti-CD2019 CAR T cells; CAR-20/19-T cells - Miltenyi Biotec; CD20-CD19-targeting CAR T Cells - Miltenyi Biotec; CD2019-targeting CAR T cells; DALY II USA; MB-CART2019.1Latest Information Update: 25 Jul 2024
At a glance
- Originator Miltenyi Biotec GmbH
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-Hodgkin's lymphoma
- Phase II Diffuse large B cell lymphoma
- Clinical Phase Unknown Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 25 Jul 2024 Miltenyi Biotec GmbH plans the phase II DALY PED trial in B cell lymphoma (Second line therapy or greater, In infants, In children, In adolescents) in April 2025 (NCT06508931)
- 28 May 2024 Miltenyi Biomedicine in collaboration with ICON completes a phase I/II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Germany (IV) (NCT03870945)
- 05 May 2024 Clinical trials in Malignant melanoma (In adolescents, In children, In adults, In the elderly, Second-line therapy or greater) in Germany (IV) (NCT06508775)